Global Blood Therapeutics Inc.

40.18+0.2100+0.53%Vol 1.01M1Y Perf -38.17%
Apr 13th, 2021 16:00 DELAYED
BID40.18 ASK40.23
Open40.21 Previous Close39.97
Pre-Market- After-Market40.18
 - -  - -%
Target Price
85.76 
Analyst Rating
Strong Buy 1.40
Potential %
113.44 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★     51.17
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap2.50B 
Earnings Rating
Sell
Price Range Ratio 52W %
7.82 
Earnings Date
5th May 2021

Today's Price Range

38.8840.39

52W Range

36.4983.69

5 Year PE Ratio Range

-15.20-18.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.97%
1 Month
-8.72%
3 Months
-19.27%
6 Months
-34.67%
1 Year
-38.17%
3 Years
-11.89%
5 Years
95.90%
10 Years
-

TickerPriceChg.Chg.%
GBT40.180.21000.53
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
7.30
8.00
0.35
0.56
-24.20
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
98.40
-352.30
-339.20
-
-
RevenueValueIndustryS&P 500US Markets
109.69M
1.76
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.97-1.00-3.09
Q03 2020-0.72-0.97-34.72
Q02 2020-1.18-0.8627.12
Q01 2020-1.47-1.2018.37
Q04 2019-1.22-1.73-41.80
Q03 2019-1.03-1.07-3.88
Q02 2019-0.95-1.01-6.32
Q01 2019-0.94-0.877.45
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.01-12.22Negative
6/2021 QR-0.96-15.66Negative
12/2021 FY-3.82-15.76Negative
12/2022 FY-1.36-1 800.00Negative
Next Report Date5th May 2021
Estimated EPS Next Report-1.01
Estimates Count13
EPS Growth Next 5 Years %-
Volume Overview
Volume1.01M
Shares Outstanding62.16M
Trades Count7.03K
Dollar Volume179.65M
Avg. Volume992.53K
Avg. Weekly Volume838.33K
Avg. Monthly Volume805.41K
Avg. Quarterly Volume981.82K

Global Blood Therapeutics Inc. (NASDAQ: GBT) stock closed at 40.18 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 1.01M shares and market capitalization of 2.50B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 389 people. Global Blood Therapeutics Inc. CEO is Ted W. Love.

The one-year performance of Global Blood Therapeutics Inc. stock is -38.17%, while year-to-date (YTD) performance is -7.23%. GBT stock has a five-year performance of 95.9%. Its 52-week range is between 36.49 and 83.69, which gives GBT stock a 52-week price range ratio of 7.82%

Global Blood Therapeutics Inc. currently has a PE ratio of -10.20, a price-to-book (PB) ratio of 6.16, a price-to-sale (PS) ratio of 22.65, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.12%, a ROC of -43.35% and a ROE of -47.32%. The company’s profit margin is -%, its EBITDA margin is -339.20%, and its revenue ttm is $109.69 Million , which makes it $1.76 revenue per share.

Of the last four earnings reports from Global Blood Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.01 for the next earnings report. Global Blood Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Global Blood Therapeutics Inc. is Strong Buy (1.4), with a target price of $85.76, which is +113.44% compared to the current price. The earnings rating for Global Blood Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Global Blood Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Global Blood Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.83, ATR14 : 2.80, CCI20 : -97.07, Chaikin Money Flow : -0.04, MACD : -2.18, Money Flow Index : 34.11, ROC : -0.62, RSI : 39.29, STOCH (14,3) : 35.92, STOCH RSI : 0.91, UO : 42.94, Williams %R : -64.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Global Blood Therapeutics Inc. in the last 12-months were: Brian Edwin Cathers (Option Excercise at a value of $0), Brian Edwin Cathers (Sold 2 200 shares of value $140 294 ), David L. Johnson (Option Excercise at a value of $0), Dawn Svoronos (Option Excercise at a value of $0), Dawn Svoronos (Sold 5 088 shares of value $325 327 ), Deval L. Patrick (Option Excercise at a value of $0), Eric Fink (Option Excercise at a value of $0), Eric Fink (Sold 6 986 shares of value $442 771 ), Glenn Pierce (Option Excercise at a value of $225 450), Jeffrey S. Farrow (Option Excercise at a value of $0), Jeffrey S. Farrow (Sold 30 416 shares of value $2 159 536 ), Jung E. Choi (Option Excercise at a value of $0), Lesley Ann Calhoun (Option Excercise at a value of $593 585), Lesley Ann Calhoun (Sold 29 403 shares of value $2 195 189 ), Mark L. Perry (Option Excercise at a value of $1 053 500), Mark L. Perry (Sold 107 200 shares of value $8 372 120 ), Philip A. Pizzo (Option Excercise at a value of $0), Scott W. Morrison (Option Excercise at a value of $0), Ted W. Love (Option Excercise at a value of $0), Ted W. Love (Sold 85 634 shares of value $6 855 948 ), Tricia Borga Suvari (Option Excercise at a value of $0), Tricia Borga Suvari (Sold 4 080 shares of value $306 000 ), Wendy L. Yarno (Option Excercise at a value of $0), Willie Brown (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
11 (78.57 %)
11 (78.57 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (20.00 %)
3 (21.43 %)
3 (21.43 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.43
Strong Buy
1.43

Global Blood Therapeutics Inc.

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

CEO: Ted W. Love

Telephone: +1 650 741-7700

Address: 171 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 389

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

49%51%

Bearish Bullish

63%37%

News

Stocktwits